Substance
ID:348264
Names and Identifiers
IUPAC name
N-(2,6-dichlorophenyl)-N-(prop-2-en-1-yl)-4,5-dihydro-1H-imidazol-2-amine
IUPAC Traditional name
alinidine
Synonyms
ST-567N-(2,6-Dichlorophenyl)-4,5-dihydro-N-2-propenyl-1H-imidazol-2-amineAlinidine
Properties
Product Information
Purity
≥98% (HPLC)
Empirical Formula (Hill Notation)
C12H13Cl2N3
Safety Information
GHS Hazard statements
H301-H315-H319-H335
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
GHS Pictograms
Acute toxicity (oral, dermal, inhalation), categories 1,2,3
GHS Precautionary statements
P261-P301+P310-P305+P351+P338
Storage Condition
under inert gas
Storage Temperature
2-8°C
RTECS
NJ1552500
Safety Statements
26
GHS Signal Word
Danger
European Hazard Symbols
Harmful (Xn)MSDS Link
Risk Statements
22-36/37/38
German water hazard class
3
Physical Property
Apperance
off-white solid
Solubility
DMSO: >10 mg/mL
Molecule Details
Caution
Air-sensitive
Biochem/physiol Actions
Alinidine is an HCN Channel blocker of neuronal Ih, related cardiac If channels and ATP-sensitive Kir channels. It is an analog of clonidine; bradycardic and antiarrhythmic agent (sinus tachyarrhythmias). Alinidine affects physiological markers in conscious dogs. Alinidine in four intravenous (i.v.) injections of 0.5, 0.5, 1, and 2 mg/kg, decreased sinus rate (< or = 43%) and ventricular rate (< or = 44%), but increased atrial rate (< or = 31%). It lengthened CSRT (< or = 71%) at the two highest doses and increased AERP (< or = 33%) and decreased WP (< or = 33%) at all doses. Alinidine did not modify mean blood pressure at any dose in either group. These results indicate that alinidine exhibits electrophysiologic effects in conscious dogs that reflect the marked antiarrhythmic potential of this agent, apart from its assumed antiischemic properties.
Air-sensitive
Biochem/physiol Actions
Alinidine is an HCN Channel blocker of neuronal Ih, related cardiac If channels and ATP-sensitive Kir channels. It is an analog of clonidine; bradycardic and antiarrhythmic agent (sinus tachyarrhythmias). Alinidine affects physiological markers in conscious dogs. Alinidine in four intravenous (i.v.) injections of 0.5, 0.5, 1, and 2 mg/kg, decreased sinus rate (< or = 43%) and ventricular rate (< or = 44%), but increased atrial rate (< or = 31%). It lengthened CSRT (< or = 71%) at the two highest doses and increased AERP (< or = 33%) and decreased WP (< or = 33%) at all doses. Alinidine did not modify mean blood pressure at any dose in either group. These results indicate that alinidine exhibits electrophysiologic effects in conscious dogs that reflect the marked antiarrhythmic potential of this agent, apart from its assumed antiischemic properties.
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data